3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
23
Breast Neoplasms
11
Fallopian Tube Neoplasms
10
Multiple Myeloma
7
Carcinoma, Ovarian Epithelial
6
Neoplasms
5
Neoplasms, Plasma Cell
3
Lymphoma
3
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Patient Participation
1
Ovarian Diseases
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Primary Effusion
1
Liver Neoplasms
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts